Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,118.39
-4.6100-0.41%
Volume:763.85K
Turnover:856.24M
Market Cap:1.06T
PE:37.54
High:1,131.44
Open:1,131.44
Low:1,115.74
Close:1,123.00
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.44
T/O Rate:0.08%
Dividend:6.69
Dividend Rate:0.60%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:31.21
PE(LYR):48.73

Loading ...

Eli Lilly's Two Clinical Trials Meet Endpoints, Plans to File Next-Generation Weight Loss Drug by 2027

Deep News
·
Jul 23

Roche Prepares for Windfall from Eli Lilly's Obesity Pill

Dow Jones
·
Jul 23

Pre-Market: Nasdaq Futures Drop 0.83% as Google and Tesla Decline; European Borrowing Costs Surge

Deep News
·
Jul 23

Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials

TIPRANKS
·
Jul 23

Lilly Targets Q1 2027 FDA Filing for Retatrutide Obesity Approval

Reuters
·
Jul 23

Eli Lilly Issues Press Release on Retatrutide Phase 3 Obesity Trial Results

Reuters
·
Jul 23

Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1c

THOMSON REUTERS
·
Jul 23

Eli Lilly: in Triumph-3, Adults with Severe Obesity & Established Cardiovascular Disease Lost up to Average of 55.8 Lbs (22.6%) at 80 Weeks

THOMSON REUTERS
·
Jul 23

Eli Lilly: Plans to Submit Biologics License Application for Retatrutide to FDA in Q1 2027

THOMSON REUTERS
·
Jul 23

India's Cipla Posts Another Profit Decline, Names Insider Dinesh Jain CFO

Reuters
·
Jul 23

Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting

THOMSON REUTERS
·
Jul 23

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

Eli Lilly Updates Financial Calendar with Quarterly Results Conference Call

Reuters
·
Jul 22

PRESS Digest-british Business - July 22

Reuters
·
Jul 22

PRESS Digest-financial Times - July 22

Reuters
·
Jul 22

Trump Announces Two-Year Zero Tariffs On Imported Generics From Aug. 1, 2026; Then 100% And 200% Hikes

MT Newswires Live
·
Jul 22

Sector Update: Healthcare

MT Newswires Live
·
Jul 22

U.S. Stocks on the Move-duke Robotics, Tesla, Hasbro

Reuters
·
Jul 22

Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising

MT Newswires Live
·
Jul 21

Eli Lilly: Rather than Compete on the Merits of Its Products, Novo is Asking Court to Stop Lilly from Communicating Results of That Trial

THOMSON REUTERS
·
Jul 21